



1052 Rec'd PCT/PTC 08 SEP 2005 PCT

Patent Docket P1982R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Aggarwal Sudeepta et al. Serial No.: 10/533,069 Filed: 28 April 2005 For: Compositions and Methods for the Treatment of Immune Related Diseases	Group Art Unit: Not Yet Assigned Examiner: Not Yet Assigned Confirmation No: Not Known CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 6, 2005 <i>Bailey Lee</i> Bailey Lee
--	---

INFORMATION DISCLOSURE STATEMENT

Commissioner - Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1) of which they are aware, which they believe may be material to the examination of this application, and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- [x] **37 CFR § 1.97(b)**
- within three months of the filing date of the application under 37 CFR § 1.53(d); or
 - within three months of the date of entry of the application as set forth in 37 CFR § 1.491, or
 - before the mailing of the first Office action on the merits of the application at the national stage of a PCT application;
 - before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

- [] **37 CFR § 1.97(c)**
- by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(iii)]. See Final Rule **1287 OG** (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 60/422,472, filed 29 October 2002 and benefit from the prior application is claimed in this application under 35 U.S.C §120. However, copies of any cited

document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).


The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: September 6, 2005

By:


David A. Carpenter
Reg. No. 45,945
Telephone No. (650)

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1982R1Serial No.
10/533,069

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Aggarwal Sudepta et al.

Filing Date

28 Apr 2005

Group

Not Assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
	1 WO 01/75166 A2	11.10.01	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

N.B.	2	Chambers and Allison, "Co-Stimulation in T Cell Responses" <u>Current Opinion in Immunology</u> 9(3):396-404 (Jun 1997)
	3	Coligan et al., "Proliferative Assays for T Cell Function" <u>Current Protocols in Immunology</u> , John Wiley & Sons, Inc., Chapter 3.12, Vol. 1 (1991)
	4	Finn and Lotze, "Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer" <u>Journal of Immunotherapy</u> 21(2):114-118 (Mar 1998)
	5	Hellstrom et al., "T cell immunity to tumor antigens" <u>Crit Rev Immunol.</u> 18(1-2):1-6 (1998)
	6	Issekutz et al., "Treatment of Established Adjuvant Arthritis in Rats with Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-Lymphocyte Migration to the Joints and Improves Clinical Disease" <u>Immunology</u> 88:569-576 (1996)
	7	Jenkins, M. K., "The Ups and Downs of T Cell Costimulation" <u>Immunology</u> 1(6):443-446 (1994)
	8	June, C. H. et al., "The B7 and CD28 Receptor Families" <u>Immunology Today</u> 15(7):321-331 (Jul 1994)
	9	Kwon et al., "Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer" <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)
	10	Linsey, P.S. et al., "The role of the CD28 receptor during T cell responses to antigen" <u>Annu Rev Immunol.</u> 11:191-212 (1993)
	11	Lynch et al., "Flt3 Ligand Induces Tumor Regression and Antitumor Immune Responses in Vivo" <u>Nature Medicine</u> 3(6):625-631 (Jun 1997)
	12	Melero et al., "Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors" <u>Nature Medicine</u> 3(6):682-685 (Jun 1997)
	13	Nickoloff et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model" <u>Am. J. Path.</u> 146(3):580-588 (Mar 1995)
	14	Schon, M. P. et al., "Murine psoriasis-like disorder induced by naive CD4+ T cells" <u>Nat. Med.</u> 3(2):183-188 (Feb 1997)
	15	Schwartz R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy" <u>Cell</u> 71(7):1065-1068 (Dec 24, 1992)

Examiner

/Nirmal Basi/ (03/28/2009)

Date Considered

03/28/2009

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.